These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10770343)

  • 1. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group.
    Walmsley S; Northfelt DW; Melosky B; Conant M; Friedman-Kien AE; Wagner B
    J Acquir Immune Defic Syndr; 1999 Nov; 22(3):235-46. PubMed ID: 10770343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma.
    Bodsworth NJ; Bloch M; Bower M; Donnell D; Yocum R;
    Am J Clin Dermatol; 2001; 2(2):77-87. PubMed ID: 11705307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials.
    Duvic M; Friedman-Kien AE; Looney DJ; Miles SA; Myskowski PL; Scadden DT; Von Roenn J; Galpin JE; Groopman J; Loewen G; Stevens V; Truglia JA; Yocum RC
    Arch Dermatol; 2000 Dec; 136(12):1461-9. PubMed ID: 11115156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alitretinoin.
    Cheer SM; Foster RH
    Am J Clin Dermatol; 2000; 1(5):307-14; discussion 315-6. PubMed ID: 11702321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma.
    Miles SA; Dezube BJ; Lee JY; Krown SE; Fletcher MA; Saville MW; Kaplan L; Groopman J; Scadden DT; Cooley T; Von Roenn J; Friedman-Kien A;
    AIDS; 2002 Feb; 16(3):421-9. PubMed ID: 11834954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alitretinoin (Panretin) gel 0.1%.
    Rhoads J
    J Assoc Nurses AIDS Care; 2001; 12(5):86-91. PubMed ID: 11565242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Kaposi's sarcoma in HIV-1 infected individuals with emphasis on resource poor settings.
    Dedicoat M; Vaithilingum M; Newton R
    Cochrane Database Syst Rev; 2003; (3):CD003256. PubMed ID: 12917957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Kaposi's sarcoma treated with topical alitretinoin].
    González de Arriba A; Pérez-Gala S; Goiriz-Valdés R; Ríos-Buceta L; García-Díez A
    Actas Dermosifiliogr; 2007; 98(1):50-3. PubMed ID: 17374335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the treatment of AIDS-related Kaposi's sarcoma.
    Cattelan AM; Trevenzoli M; Aversa SM
    Am J Clin Dermatol; 2002; 3(7):451-62. PubMed ID: 12180893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial.
    Aboulafia DM; Norris D; Henry D; Grossman RJ; Thommes J; Bundow D; Yocum RC; Stevens V
    Arch Dermatol; 2003 Feb; 139(2):178-86. PubMed ID: 12588223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kaposi's sarcoma: new topical treatment approved.
    James JS
    AIDS Treat News; 1999 Feb; (No 313):1. PubMed ID: 11366235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KS drug goes to FDA. Food and Drug Administration.
    GMHC Treat Issues; 1998 May; 12(5):7. PubMed ID: 11365479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: results of a sequential non-randomized phase II trial. Kaposi's Sarcoma ANRS Study Group. Agence Nationale de Recherches sur le SIDA.
    Saiag P; Pavlovic M; Clerici T; Feauveau V; Nicolas JC; Emile D; Chastang C
    AIDS; 1998 Nov; 12(16):2169-76. PubMed ID: 9833858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study.
    Gill PS; Espina BM; Moudgil T; Kidane S; Esplin JA; Tulpule A; Levine AM
    Leukemia; 1994; 8 Suppl 3():S26-32. PubMed ID: 7808021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical 0.1% alitretinoin gel for classic Kaposi sarcoma.
    Morganroth GS
    Arch Dermatol; 2002 Apr; 138(4):542-3. PubMed ID: 11939830
    [No Abstract]   [Full Text] [Related]  

  • 16. AIDS-related Kaposi sarcoma: the role of local therapy for a systemic disease.
    Dezube BJ
    Arch Dermatol; 2000 Dec; 136(12):1554-6. PubMed ID: 11115173
    [No Abstract]   [Full Text] [Related]  

  • 17. Open-label pilot study of alitretinoin gel 0.1% in the treatment of photoaging.
    Baumann L; Vujevich J; Halem M; Martin LK; Kerdel F; Lazarus M; Pacheco H; Black L; Bryde J
    Cutis; 2005 Jul; 76(1):69-73. PubMed ID: 16144296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
    Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
    AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.
    Koon HB; Krown SE; Lee JY; Honda K; Rapisuwon S; Wang Z; Aboulafia D; Reid EG; Rudek MA; Dezube BJ; Noy A
    J Clin Oncol; 2014 Feb; 32(5):402-8. PubMed ID: 24378417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
    Noy A; Scadden DT; Lee J; Dezube BJ; Aboulafia D; Tulpule A; Walmsley S; Gill P
    J Clin Oncol; 2005 Feb; 23(5):990-8. PubMed ID: 15598977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.